Telix Pharmaceuticals reports positive TLX591-Tx Phase 3 results

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company released encouraging Part 1 results from its global Phase 3 ProstACT study of TLX591-Tx, its novel prostate cancer therapy. Key results showed the therapy demonstrated an acceptable and manageable safety profile, with no new safety signals and sustained tumour uptake across patients.

What did Telix Pharmaceuticals report?

• ProstACT Global Phase 3 (Part 1) met key objectives for safety, pharmacokinetics, and dosimetry.
• No new safety signals or adverse drug–drug interactions were observed in the study.
• Low radiation exposure to salivary glands and kidneys, supporting tolerability.
• Most prevalent side effects were fatigue (53%), nausea (28%), and dry mouth (25%), with nearly all cases being mild or moderate.
• Platelet counts recovered to safe levels on average 15 days after treatment nadir.

What else do investors need to know?

The ProstACT Global study enrolled 36 patients with advanced prostate cancer, all of whom received two doses of TLX591-Tx in combination with standard therapies. Thirty-two patients remain alive, and 26 are continuing in the trial.

Telix emphasised that TLX591-Tx offers a patient-friendly, two-dose regimen, aiding treatment compliance and integration with existing standards of care. The therapy’s pharmacokinetic profile showed sustained tumour retention and consistent results across different patient cohorts.

What’s next for Telix Pharmaceuticals?

With Part 1 complete, Telix is seeking regulatory clearance to begin Part 2 of the Phase 3 trial in the US. Enrolment is already under way in Australia, New Zealand, and Canada, with further approvals obtained in Asia and Europe.

The company plans to continue expanding the study globally, with the ultimate goal of demonstrating long-term clinical benefit and securing approval for TLX591-Tx as a new treatment option for patients with metastatic prostate cancer.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix Pharmaceuticals shares have declined 63%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 8% over the same period.

View Original Announcement

The post Telix Pharmaceuticals reports positive TLX591-Tx Phase 3 results appeared first on The Motley Fool Australia.

More reading

• Westgold Resources gives green light to $145m Higginsville expansion
• Air New Zealand suspends earnings guidance as jet fuel prices soar
• Thinking of selling your ASX shares today? Here’s why it would be a big mistake
• Here are the top 10 ASX 200 shares today
• Why almost every ASX sector is falling in today’s market sell-off

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.